Table of Contents  
NEWS AND VIEWS
Year : 2013  |  Volume : 4  |  Issue : 1  |  Page : 74-75  

Continuing β-blockers after noncardiac surgery improves patient outcomes and lowers mortality


Department of Pharmacology, Indira Gandhi Medical College and Research Institute, Kadhirkamam, Puducherry, India

Date of Web Publication22-Feb-2013

Correspondence Address:
G Sivagnanam
Department of Pharmacology, Indira Gandhi Medical College and Research Institute, Kadhirkamam, Puducherry
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

How to cite this article:
Sivagnanam G. Continuing β-blockers after noncardiac surgery improves patient outcomes and lowers mortality. J Pharmacol Pharmacother 2013;4:74-5

How to cite this URL:
Sivagnanam G. Continuing β-blockers after noncardiac surgery improves patient outcomes and lowers mortality. J Pharmacol Pharmacother [serial online] 2013 [cited 2019 Nov 15];4:74-5. Available from: http://www.jpharmacol.com/text.asp?2013/4/1/74/107696


   News Top

"Failing to continue beta-blocker therapy during the perioperative period was associated with a nearly two-fold risk of 90-day combined adverse events, including death" [1]


   (Re) Views Top


In a study to determine the effect of β-blocker continuation on outcomes in patients undergoing elective noncardiac surgery, it was found that (after adjusting for risk characteristics), failure to continue β-blocker treatment was associated with a nearly two-fold risk of 90-day combined adverse event (odds ratio, 1.97; 95% CI, 1.19-3.26). The odds were even greater among patients with higher cardiac risk (odds ratio, 5.91; 95% CI, 1.40-25.00). The odds of combined adverse events continued to be elevated 1 year postoperatively (odds ratio, 1.66; 95% CI, 1.08-2.55). It was concluded that β-blocker continuation on the day of and after surgery was associated with fewer cardiac events and lower 90-day mortality. [2]

In a supportive commentary to the above study, β-blocker continuation has been emphasized (though this aspect was raged in controversy for more than 20 years), by quoting a study undertaken in 1996, that perioperative β-blockade reduced cardiac mortality for up to 2 years following surgery. [3]

 
   References Top

1.Available from: http://www.ahrq.gov/research/dec12/1212RA4.htm [Last accessed on 2012 Dec 10].  Back to cited text no. 1
    
2.Kwon S, Thompson R, Florence M, Maier R, McIntyre L, Rogers T, et al. Surgical Care and Outcomes Assessment Program (SCOAP) Collaborative. β-blocker continuation after noncardiac surgery: A report from the surgical care and outcomes assessment program. Arch Surg 2012;147:467-73.  Back to cited text no. 2
[PUBMED]    
3.Neumayer L. To block or not to block?: Comment on "β-blocker continuation after surgery". Arch Surg 2012;147:473.  Back to cited text no. 3
    




 

Top
  
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
   News
   (Re) Views
    References

 Article Access Statistics
    Viewed828    
    Printed44    
    Emailed0    
    PDF Downloaded176    
    Comments [Add]    

Recommend this journal